Targeted Biologic and Cellular Therapies for Systemic Lupus Erythematosus: Current Evidence and Future Perspectives

Abstract

Context: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by heterogeneous clinical manifestations and dysregulated innate and adaptive immune responses. Conventional management relies largely on immunosuppressants, which pose challenges for long-term efficacy and sustained disease control. Recent therapeutic advances have introduced monoclonal antibodies as a more targeted approach to disease control. Evidence Acquisition: A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and Embase from database inception to early 2026. The review included randomized controlled trials, pivotal phase II/III trials, long-term extension trials, observational cohort studies, systematic reviews and meta-analyses, and regulatory documents from the FDA and the EMA. Results: Anifrolumab, a monoclonal antibody that inhibits the type I interferon pathway, appears to improve SLE manifestations and to enable sustained reductions in the corticosteroid dose. B-cell-targeted therapies, including belimumab, rituximab, and obinutuzumab, together with novel agents targeting other immune pathways, offer promising therapeutic alternatives. Although several novel therapies have demonstrated clinical benefit in SLE, other experimental approaches, such as ustekinumab, have failed to show significant efficacy. Cell-based therapies, including anti-CD19 chimeric antigen receptor T-cell therapy, are emerging as investigational options for refractory disease. Conclusions: Emerging targeted and cell-based therapies represent a promising direction in SLE management by enabling more precise strategies for treatment-resistant disease; however, careful evaluation of their long-term safety, effectiveness, and accessibility is required.